Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BMS-767778
- Development stage
- Discontinued
- Lead developer
- Bristol Myers Squibb
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
BMS-767778 is an orally active small molecule developed by Bristol Myers Squibb as a selective inhibitor of dipeptidyl peptidase 4 (DPP4), also known as CD26 antigen. It was investigated for the treatment of type 2 diabetes mellitus due to its antihyperglycemic properties. The compound belongs to the chemical classes of pyridines and pyrroles and acts by inhibiting DPP4 activity with high potency (Ki = 0.9 nM), thereby increasing incretin levels and improving glycemic control. Clinical development reached phase I trials but was subsequently discontinued for type 2 diabetes mellitus[1][2][3][4].
- Other names
- 915729-95-289FYR7JU5AUNII-89FYR7JU5AUNII89FYR7JU5AUNII 89FYR7JU5A2-(3-(aminomethyl)-4-(2,4-dichlorophenyl)-2-methyl-5-oxo-7H-pyrrolo(3,4-b)pyridin-6-yl)-N,N-dimethyl-acetamide
02
Targets
DPP-4 (Dipeptidyl Peptidase-IV)
Beyond the preview
Go deeper on BMS-767778.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BMS-767778.